September 11, 2017
Biophytis presents the mechanism of action of Macuneos for the treatment of AMD, at the Euretina Congress. Read the Press Release
Biophytis presents the mechanism of action of Macuneos for the treatment of AMD, at the Euretina Congress. Read the Press Release
Biophytis clinical stage drug-candidate Sarconeos demonstrates efficacy in preclinical models of Duchenne muscular dystrophy . Read the Press Release
The report of the Key Opinion Leader Breakfast of july 28, in NYC with Roger Fielding, PhD (Tufts University) made available
Biophytis announces the appointment of Dr Manfred Horst as Business Development Office. Read the Press Release
2016 Reference Document made available. Read the Press Release
BIOPHYTIS selects Appletree CI Group to conduct MACA-OBS, and releases the MACA clinical program schedule of Macuneos in dry AMD. Read the Press Release
Biophytis to Host Key Opinion Leader Breakfast on Sarcopenia in New York – July 28, 8:00 am
Biophytis announces the issuance of a €3 million tranche of ORNANEBSA. Read the Press Release
Video interview of Stanislas Veillet, CEO of Biophytis : “The schedule announced last year is followed”. Click here to watch the vidéo.
Participation of Biophytis to the European MIDCAP event in Hotel Pullman Paris Eiffel Tour – June 28 & 29, 2017